Ivacaftor; Ivacaftor, Tezacaftor Patent Expiration
Ivacaftor; Ivacaftor, Tezacaftor is Used for treating cystic fibrosis in patients with specific CFTR mutations, aged 6 and older. It was first introduced by Vertex Pharmaceuticals Inc
Ivacaftor; Ivacaftor, Tezacaftor Patents
Given below is the list of patents protecting Ivacaftor; Ivacaftor, Tezacaftor, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Symdeko (copackaged) | US10022352 | Modulators of ATP-binding cassette transporters | Apr 09, 2027 | Vertex Pharms Inc |
| Symdeko (copackaged) | US10058546 | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof | Jul 15, 2033 | Vertex Pharms Inc |
| Symdeko (copackaged) | US10081621 | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide | Mar 25, 2031 | Vertex Pharms Inc |
| Symdeko (copackaged) | US10206877 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | Apr 14, 2035 | Vertex Pharms Inc |
| Symdeko (copackaged) | US10239867 | Modulators of ATP-binding cassette transporters | Apr 09, 2027 | Vertex Pharms Inc |
| Symdeko (copackaged) | US10646481 | Pharmaceutical composition and administrations thereof | Aug 13, 2029 | Vertex Pharms Inc |
| Symdeko (copackaged) | US11564916 | Pharmaceutical composition and administrations thereof | Aug 13, 2029 | Vertex Pharms Inc |
| Symdeko (copackaged) | US11578062 | Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide | Mar 25, 2031 | Vertex Pharms Inc |
| Symdeko (copackaged) | US11639347 | Modulators of ATP-binding cassette transporters | Apr 09, 2027 | Vertex Pharms Inc |
| Symdeko (copackaged) | US11951212 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | Apr 14, 2035 | Vertex Pharms Inc |
| Symdeko (copackaged) | US7495103 | Modulators of ATP-binding cassette transporters | May 20, 2027 | Vertex Pharms Inc |
| Symdeko (copackaged) | US7645789 | Indole derivatives as CFTR modulators | May 01, 2027 | Vertex Pharms Inc |
| Symdeko (copackaged) | US7776905 | Modulators of ATP-binding cassette transporters | Jun 03, 2027 | Vertex Pharms Inc |
| Symdeko (copackaged) | US8324242 | Modulators of ATP-binding cassette transporters | Aug 05, 2027 | Vertex Pharms Inc |
| Symdeko (copackaged) | US8354427 | Modulators of ATP-binding cassette transporters | Jul 06, 2026 | Vertex Pharms Inc |
| Symdeko (copackaged) | US8410274 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | Dec 28, 2026 | Vertex Pharms Inc |
| Symdeko (copackaged) | US8415387 | Modulators of ATP-binding cassette transporters | Nov 12, 2027 | Vertex Pharms Inc |
| Symdeko (copackaged) | US8598181 | Modulators of ATP-binding cassette transporters | May 01, 2027 | Vertex Pharms Inc |
| Symdeko (copackaged) | US8623905 | Modulators of ATP-binding cassette transporters | May 01, 2027 | Vertex Pharms Inc |
| Symdeko (copackaged) | US8629162 | Modulators of ATP-binding cassette transporters | Jun 24, 2025 | Vertex Pharms Inc |
| Symdeko (copackaged) | US8754224 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | Dec 28, 2026 | Vertex Pharms Inc |
| Symdeko (copackaged) | US9012496 | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof | Jul 15, 2033 | Vertex Pharms Inc |
| Symdeko (copackaged) | US9670163 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | Dec 28, 2026 | Vertex Pharms Inc |
| Symdeko (copackaged) | US9931334 | Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | Dec 28, 2026 | Vertex Pharms Inc |
| Symdeko (copackaged) | US9974781 | Modulators of ATP-binding cassette transporters | Apr 09, 2027 | Vertex Pharms Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ivacaftor; Ivacaftor, Tezacaftor's patents.
Latest Legal Activities on Ivacaftor; Ivacaftor, Tezacaftor's Patents
Given below is the list recent legal activities going on the following patents of Ivacaftor; Ivacaftor, Tezacaftor.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Patent Issue Date Used in PTA Calculation | 09 Apr, 2024 | US11951212 |
| Patent eGrant Notification | 09 Apr, 2024 | US11951212 |
| Recordation of Patent eGrant | 09 Apr, 2024 | US11951212 |
| Mail Patent eGrant Notification | 09 Apr, 2024 | US11951212 |
| Email Notification | 09 Apr, 2024 | US11951212 |
| Recordation of Patent Grant Mailed | 09 Apr, 2024 | US11951212 |
| Email Notification | 21 Mar, 2024 | US11951212 |
| Issue Notification Mailed | 20 Mar, 2024 | US11951212 |
| Dispatch to FDC | 05 Mar, 2024 | US11951212 |
| Application Is Considered Ready for Issue | 05 Mar, 2024 | US11951212 |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳